Press Releases

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in the Phase III registrational trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China. The fixed-duration treatment of ICP-248 in combination

Eli Lilly and Company (LLY) has expanded its LillyDirect digital healthcare platform to offer connections to independent in-person and telehealth options for people in the U.S. living with Alzheimer's disease, the majority of whom have not been formally diagnosed.1 Both clinicians and people living with Alzheimer's disease have expressed the need to increase the capacity of our health care systems to diagnose and manage more of the nearly 7 million Americans living with the

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatment that modify the natural history of knee osteoarthritis, announces that it has been authorized by Health Canada to launch the Phase 2a INFLAM MOTION “Proof-of-Concept” study for 4P004 in patients with knee osteoarthritis. The INFLAM MOTION Study is a Phase 2a multicenter, randomized, double-blind, placebo-controlled trial conducted in the EU, US, and Canada, including three sites in Cana

Simplivia, a global leader in innovative drug delivery solutions, is proud to announce its participation in the ISOPP CAPhO 2025 Symposium where innovation in drug handling takes center stage. Simplivia is excited to launch its products in Canada and showcase its latest advancements, including the Chemfort® Closed System Drug Transfer Device (CSTD) and the recently launched SmartCompounders automated solution. At the forefront is Chemfort®, a drug-binding mechanical barrier

Cirius Therapeutics, Inc., developing innovative therapies for patients suffering with diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced that its executives will be speaking at the following upcoming healthcare conferences: MedInvest Biotech & Pharma Investor Conference1 in New York, NY on Friday, March 28. 2:20 PM ET: Phase 2b-proven Clinical Candidate 0602K Under Development for Obesity/Overweight,

Eli Lilly and Company today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30 in Chicago. In an oral presentation, Lilly, in collaboration with Foghorn Therapeutics, will present new preclinical data for LY4050784, a selective inhibitor of SMARCA2, in combination with chemotherapy, pembrolizumab, and KRAS inhibitors in precl

Valneva SE, a specialty vaccine company, today announced that it is responding to the rapidly escalating chikungunya epidemic on the French island of La Réunion with its IXCHIQ ® vaccine . In agreement with and with the support of the Réunion Regional Health Agency, Valneva will supply 40,000 doses starting in early April, with the possibility of supplying more through distribution agreements with wholesale distributors on the island. This supply of doses, covered by the aut

on clAptarGroup, Inc.  a global leader in drug and consumer product dosing, dispensing and protection technologies, has been recognized for its leadership imate change topics by the global environmental non-profit CDP, securing a place on its prestigious “A List.” Aptar was recognized for its actions to cut emissions, mitigate climate risks and further the low-carbon economy, based on the data reported by the Company through CDP’s 2024 corporate questionnaire.

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (“NMPA”) has approved the supplemental new drug application (“sNDA”) for the company’s product, toripalimab, in combination with bevacizumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (&ldquo

Opthea Limited,a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD. The global COAST Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in